Navigation

TA107 Breast cancer (early) - trastuzumab: information for the public

The summary of the key recommendations on on trastuzumab (herceptin) for the adjuvant treatment of early-stage HER2-positive breast cancer. It is written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets or any other suitable publication.

This page was last updated: 28 December 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.